Unfortunately, despite the biologic rationale and efficacy demonstrated by BCL2 inhibition in other hematological malignancies, our preliminary experience showed that venetoclax monotherapy had therapeutic activity in only 18% of patients, with one case of CR. The gene discussed is BCL2; the disease is hematologic disorder.